Invitrogen™ Palivizumab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA541718

Catalog No. PIMA541718

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process.

Specifications

• Antigen: Palivizumab Humanized
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: MEDI-493; Synagis
• Immunogen: Respiratory syncytial virus- RSV.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid
• Target Molecule: Chemical

• Applications: ELISA, SDS-Page
• Concentration: 2.47 mg/mL
• Formulation: PBS with no preservative; pH 7.4
• Host Species: Human
• Purification Method: Protein A/G
• Regulatory Status: RUO
• Target Species: Virus
• Product Type: Antibody
• Isotype: IgG1 κ

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov